BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29587879)

  • 1. Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.
    Eaton N; Cabanas H; Balinas C; Klein A; Staines D; Marshall-Gradisnik S
    BMC Pharmacol Toxicol; 2018 Mar; 19(1):12. PubMed ID: 29587879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Huth TK; Staines D; Marshall-Gradisnik S
    J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP
    Eaton-Fitch N; Cabanas H; du Preez S; Staines D; Marshall-Gradisnik S
    J Transl Med; 2021 Jul; 19(1):306. PubMed ID: 34266470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients.
    Balinas C; Cabanas H; Staines D; Marshall-Gradisnik S
    J Transl Med; 2019 Dec; 17(1):401. PubMed ID: 31796045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome.
    Eaton-Fitch N; du Preez S; Cabanas H; Staines D; Marshall-Gradisnik S
    Syst Rev; 2019 Nov; 8(1):279. PubMed ID: 31727160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis.
    Brenu EW; van Driel ML; Staines DR; Ashton KJ; Hardcastle SL; Keane J; Tajouri L; Peterson D; Ramos SB; Marshall-Gradisnik SM
    J Transl Med; 2012 May; 10():88. PubMed ID: 22571715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Cabanas H; Muraki K; Eaton N; Balinas C; Staines D; Marshall-Gradisnik S
    Mol Med; 2018 Aug; 24(1):44. PubMed ID: 30134818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis.
    Huth TK; Brenu EW; Ramos S; Nguyen T; Broadley S; Staines D; Marshall-Gradisnik S
    Scand J Immunol; 2016 Jan; 83(1):44-51. PubMed ID: 26381393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.
    Cabanas H; Muraki K; Staines D; Marshall-Gradisnik S
    Front Immunol; 2019; 10():2545. PubMed ID: 31736966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels.
    Nguyen T; Johnston S; Clarke L; Smith P; Staines D; Marshall-Gradisnik S
    Clin Exp Immunol; 2017 Feb; 187(2):284-293. PubMed ID: 27727448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.
    Cabanas H; Muraki K; Eaton-Fitch N; Staines DR; Marshall-Gradisnik S
    Front Immunol; 2021; 12():687806. PubMed ID: 34326841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients.
    Eaton-Fitch N; Du Preez S; Cabanas H; Muraki K; Staines D; Marshall-Gradisnik S
    J Transl Med; 2022 Feb; 20(1):94. PubMed ID: 35172836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).
    Hardcastle SL; Brenu EW; Johnston S; Nguyen T; Huth T; Wong N; Ramos S; Staines D; Marshall-Gradisnik S
    BMC Immunol; 2015 Jun; 16():35. PubMed ID: 26032326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients.
    Cabanas H; Muraki K; Balinas C; Eaton-Fitch N; Staines D; Marshall-Gradisnik S
    Mol Med; 2019 Apr; 25(1):14. PubMed ID: 31014226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.
    Brenu EW; van Driel ML; Staines DR; Ashton KJ; Ramos SB; Keane J; Klimas NG; Marshall-Gradisnik SM
    J Transl Med; 2011 May; 9():81. PubMed ID: 21619669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
    Cliff JM; King EC; Lee JS; Sepúlveda N; Wolf AS; Kingdon C; Bowman E; Dockrell HM; Nacul L; Lacerda E; Riley EM
    Front Immunol; 2019; 10():796. PubMed ID: 31057538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
    Rivas JL; Palencia T; Fernández G; García M
    Front Immunol; 2018; 9():1028. PubMed ID: 29867995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a multi-site clinical assessment of ME/CFS (MCAM) sub-study.
    Querec TD; Lin JS; Chen Y; Helton B; Kogelnik AM; Klimas NG; Peterson DL; Bateman L; Lapp C; Podell RN; Natelson BH; Unger ER;
    J Transl Med; 2023 Apr; 21(1):242. PubMed ID: 37013608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study.
    Mensah F; Bansal A; Berkovitz S; Sharma A; Reddy V; Leandro MJ; Cambridge G
    Clin Exp Immunol; 2016 May; 184(2):237-47. PubMed ID: 26646713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients.
    Nguyen T; Staines D; Nilius B; Smith P; Marshall-Gradisnik S
    Biol Res; 2016 May; 49(1):27. PubMed ID: 27245705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.